GE's research and development organization, GE Global Research, has partnered with pharmaceutical giant Eli Lilly in a three-year collaborative research agreement to discover and develop in vitro diagnostic assays for predicting cancer treatment response to targeted therapies.
Lilly is developing targeted cancer therapeutics, while GE is developing multiplexed tissue-based assays and image analysis tools to measure multiple biological pathways, according to GE of Niskayuna, NY, and Lilly of Indianapolis. The firms hope the collaboration will discover key proteins and gene signatures to predict the likelihood that a medication will be effective in treating certain cancers.
GE will receive access to clinical tissue samples from unidentified patients enrolled in Lilly's clinical trials, while Lilly will be able to utilize GE's technologies in automated tissue-based image analysis and molecular reagents.
By AuntMinnie.com staff writers
October 1, 2007
Related Reading
GE to sell Imtec conebeam CT scanner, September 18, 2007
GE launches pediatric DEXA software, September 17, 2007
GE, NCHL launch institute, August 29, 2007
GE signs supply pact with Novation, August 28, 2007
GE launches emergency US education program, August 24, 2007
Copyright © 2007 AuntMinnie.com
